Cdc11 activators represent a collection of chemical compounds that indirectly facilitate the functional activity of Cdc11, primarily through their influence on cell cycle regulation and cytoskeletal dynamics. Compounds such as Paclitaxel and Nocodazole, which modulate microtubule stability, play a pivotal role in enhancing Cdc11 activity. Paclitaxel stabilizes microtubules, thereby promoting spindle assembly and function, crucial for the cytokinetic role of Cdc11 in septin ring formation. Conversely, Nocodazole disrupts microtubule polymerization, triggering cell cycle checkpoints that depend on Cdc11 for proper spindle orientation. Similarly, Roscovitine and Purvalanol A, selective CDK inhibitors, indirectly boost Cdc11 activity by modulating cell cycle transitions, particularly the G2/M phase, where Cdc11's role is critical. Additionally, Latrunculin A, by disrupting actin polymerization, affects cytoskeletal organization, essential for Cdc11-involved septin ring positioning.
Further enhancing Cdc11 activity are compounds targeting spindle dynamics and kinetochore functions. Monastrol and S-Trityl-L-cysteine, as inhibitors of the kinesin Eg5, affect spindle pole formation, indirectly augmenting Cdc11's role in cell division. The Aurora kinase inhibitors, ZM447439 and Alisertib, and the Plk1 inhibitor, BI 2536, contribute to Cdc11 activation by impacting chromosome alignment and spindle checkpoint mechanisms. These processes are integral to Cdc11's functionality in cell division. Dimethylenastron, another Eg5 inhibitor, and Thiabendazole, which inhibits microtubule polymerization, further underscore the intricate relationship between spindle dynamics and Cdc11 activity. By inducing stress responses and cell cycle checkpoints, these compounds highlight the dependence of Cdc11's functional efficacy on the cellular context, particularly in spindle orientation and septin ring assembly during critical phases of cell division. Collectively, these activators, through their targeted modulation of cellular mechanisms, underscore the complex regulatory network that governs Cdc11's activity, emphasizing its integral role in maintaining cellular homeostasis through precise cytoskeletal and cell cycle regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Stabilizes microtubules, enhancing Cdc11 activity by promoting spindle assembly and function, crucial for Cdc11's role in cytokinesis and septin ring formation. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
A selective CDK inhibitor, enhances Cdc11 activity by modulating cell cycle progression, especially at the G2/M transition where Cdc11 is critical. | ||||||
Monastrol | 254753-54-3 | sc-202710 sc-202710A | 1 mg 5 mg | $120.00 $233.00 | 10 | |
An Eg5 kinesin inhibitor, indirectly enhances Cdc11 activity by affecting spindle assembly and impacting cell division processes where Cdc11 is essential. | ||||||
S-Trityl-L-cysteine | 2799-07-7 | sc-202799 sc-202799A | 1 g 5 g | $32.00 $66.00 | 6 | |
Inhibits the mitotic kinesin Eg5, indirectly enhancing Cdc11 activity by interfering with spindle dynamics and impacting septin ring formation and cell division. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
A CDK inhibitor targeting CDK1/cyclin B, enhances Cdc11 activity by modulating cell cycle phases where Cdc11's function in septin dynamics is critical. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
An Aurora kinase inhibitor, enhances Cdc11 activity by affecting chromosome alignment and spindle checkpoint, processes involving Cdc11. | ||||||
BI6727 | 755038-65-4 | sc-364432 sc-364432A sc-364432B sc-364432C sc-364432D | 5 mg 50 mg 100 mg 500 mg 1 g | $150.00 $1050.00 $1665.00 $3329.00 $4382.00 | 1 | |
A Plk1 inhibitor, enhances Cdc11 activity by affecting spindle formation and cytokinesis, processes in which Cdc11 is critically involved. | ||||||
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Inhibits Aurora A kinase, enhancing Cdc11 activity by impacting spindle assembly and stability, crucial for Cdc11’s role in cell division and septin ring dynamics. | ||||||
Eg5 Inhibitor III, Dimethylenastron | 863774-58-7 | sc-221576 sc-221576A sc-221576B sc-221576C | 1 mg 5 mg 10 mg 25 mg | $38.00 $132.00 $244.00 $516.00 | 1 | |
An Eg5 inhibitor, indirectly enhances Cdc11 activity by affecting spindle dynamics and cell cycle phases where Cdc11 is essential for septin ring formation. | ||||||
Thiabendazole | 148-79-8 | sc-204913 sc-204913A sc-204913B sc-204913C sc-204913D | 10 g 100 g 250 g 500 g 1 kg | $32.00 $84.00 $183.00 $312.00 $572.00 | 5 | |
Inhibits microtubule polymerization, enhancing Cdc11 activity by inducing cell cycle checkpoints and stress responses relying on Cdc11's function in spindle orientation. | ||||||